Stock ANTX AN2 THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases AN2 Therapeutics, Inc.

Equities

ANTX

US0373261058

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
2.37 USD +2.16% Intraday chart for AN2 Therapeutics, Inc. +0.42% -88.43%
Apr. 03 North American Morning Briefing : Powell Awaited -2- DJ
Apr. 02 JMP Securities Upgrades AN2 Therapeutics to Market Outperform From Market Perform MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights
BU
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results
AQ
Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX
PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX
PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX
PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX
PR
AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex Lung Disease
AQ
AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease
BU
AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference
BU
AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights
BU
AN2 Therapeutics to Present at Upcoming Investor Conferences
BU
AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease
BU
AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023
BU
AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria
BU
AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex Lung Disease
AQ
AN2 Therapeutics : Company announces Phase 2 part of the EBO-301 trial is now fully enrolled with 80 patients; Topline Phase 2 trial results expected in summer 2024 Over 100 sites across four countries (U.S., Japan, S. Korea & Australia) as epetraborole enters Phase 3 portion of EBO-301; expected to enroll ~230 patients - Form 8-K
PU
AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease
BU
AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock
BU
AN2 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights
BU
AN2 THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ANTX Stock
  4. News AN2 Therapeutics, Inc.
  5. Press Releases